Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Two Doses of Nitric Oxide (NO) Given Intermittently Via Inhalation to Subjects With Bronchiolitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Pediatric subjects up to 12-months of age, including subjects born ≥ 28 weeks of gestation.~2. Subjects with acute bronchiolitis requiring in-patient hospitalization expected to last 24 hours or more.~3. Modified Tal Score (mTal) between 7 to 10 at screening. Note that the oxygen requirement section of the clinical score reflects patient's oxygen saturation without oxygen supplementation.~4. Screening SpO2 of 92% or less in room-air~5. A parent/guardian who is willing to comply with the study procedures and signs an informed consent on behalf of the subject.~Exclusion Criteria:~1. Subjects diagnosed with alveolar pneumonia by chest X-ray and white blood cell (WBC)≥ 15,000/ul and Temp \>39°C~2. Previous diagnosis of asthma or cough lasting more than 4 weeks or chronic requirement for asthma medications.~3. Subjects with 2 or more previous physician diagnosed wheezing episodes.~4. Any previous intensive care unit admission for respiratory distress or respiratory-related illness~5. Diagnosis of Bronchopulmonary Dysplasia (BPD) based on medical history and home oxygen use.~6. Subjects on home oxygen use for any reason~7. Presence or use of a nasogastric or orogastric feeding tube~8. Subjects with history of methemoglobinemia, known hereditary methemoglobinemia, and/or methemoglobin \>2% for any cause.~9. Use of an investigational drug or device within 30 days before enrollment and/or expected to participate in a new study within 90 days of enrollment.~10. History of frequent epistaxis (\>1 episode/month) or significant hemoptysis within 30 days prior to enrollment (≥5 mL of blood in one coughing episode)~11. Taken medications such as chronic systemic corticosteroids, central nervous system (CNS) stimulants, theophylline or aminophylline, anti-arrhythmic within 30 days of screening.~12. Diagnosed with an underlying condition, which significantly affects respiratory system:~    1. Cystic fibrosis (CF), primary ciliary dyskinesia, non-CF bronchiectasis~   2. Immune deficiency~   3. Genetic or neurological disorder capable of causing:~       * Impaired respiratory secretions clearance including insufficient cough~      * chronic respiratory failure and insufficiency~      * restrictive lung disease~   4. Conditions that decrease the muscle strength~   5. Glucose 6-phosphate dehydrogenase deficiency~   6. 6-Phosphogluconate dehydrogenase deficiency~   7. Trisomy 21 (Down Syndrome)~13. Presence of upper airway anomalies that may interfere with breathing, including:~    1. Choanal atresia or stenosis~   2. Cleft lip and palate~   3. Tracheo-esophageal fistula~   4. Tracheal stenosis~   5. Tracheomalacia and/or bronchomalacia~14. History of severe aspiration pneumonia~15. Having the following signs or symptoms:~    1. clinically significant pulmonary (lung) and/or cardiac (heart) congenital malformations~   2. an underlying renal, or liver insufficiency, immunodeficiency, encephalopathy;~   3. known or suspected foreign body aspiration during enrollment.~16. If the first treatment cannot start within 6 hours after signing of the informed consent form (ICF), the subject is not eligible for enrollment.~17. Symptoms (i.e., cough and wheezing) started longer than 72 h before admission to the hospital~18. Per Investigator's discretion, the subject parents/legal guardian(s) are unable to comply with the study procedures.~19. Any reason that, in the opinion of the investigator, may make the subject unfit for this clinical trial.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- Group 1- NO treatment- dose 1 (Type: EXPERIMENTAL): Will comprise of approximately 30 patients and will receive inhalations of dose 1 of NO combined with O2/air for 40 minutes, every 4.5 hours during the day four times a day for up to 5 days in addition to standard supportive treatment.
- Group 2- NO treatment- dose 2 (Type: EXPERIMENTAL): Will comprise of approximately 30 patients and will receive inhalations of dose 2 of NO combined with O2/air for 40 minutes, every 4.5 hours during the day four times a day for up to 5 days in addition to standard supportive treatment.
- Group 3- Control treatment (Type: OTHER): Will comprise of approximately 30 patients and will receive O2/air using the same treatment schedule and equipment as groups 1 and 2, in addition to standard supportive treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).